Opinion statement
The landscape of therapeutic options for HCV infection has dramatically changed with the approval of all-oral direct-acting antiviral (DAA) regimens. DAAs target important steps in the HCV viral life cycle, resulting in higher response rates and fewer adverse events than were afforded with interferon and ribavirin, the prior standard of care. The achievement of sustained virologic response (SVR) rates in excess of 90% with use of DAA regimens has not only been translated into HCV eradication for the hundreds of thousands treated but is also anticipated to decrease the incidence of major complications associated with chronic HCV infection. Additionally, the favorable side effect profile of DAAs has made HCV therapy feasible in difficult-to-treat populations, including those with previous exposure to interferon and ribavirin, cirrhosis, decompensated liver disease, HIV and HCV co-infection, and severe renal dysfunction/end-stage renal disease. Given this tremendous progress, all patients infected with HCV infection should be treated.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Choo QL, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359–62.
van der Meer AJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.
Mohd Hanafiah K, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.
Smith BD, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32.
Messina JP, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.
Harvoni package insert. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf.
Viekira XR package insert. http://www.rxabbvie.com/pdf/viekiraxr_pi.pdf.
Zepatier package insert. https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf.
Epclusa package insert. http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf.
Solvaldi package insert. http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf.
Daklinza package insert. http://packageinserts.bms.com/pi/pi_daklinza.pdf.
Olysio package insert. https://www.olysio.com/shared/product/olysio/prescribing-information.pdf.
•• AASLD/IDSA/IAS-USA HCV guidance: recommendations for testing, managing and treating hepatitis C. http://www.hcvguidelines.org/. 2016.Guidance document outlining suggested hepatitis C treatment regimens based on most up to date research.
Liu R, et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother. 2015;59(11):6922–9.
Summa V, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56(8):4161–7.
Howe AY, et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014;59(12):1657–65.
• Zeuzem S, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.Phase 3 trial in treatment naive patients supporting the efficacy of the elbasvir/grazoprevir fixed dose combination for treatment of chronic hepatitis C infection.
Kwo P, Gani E, Peng CY, et al. Efficacy and safety of grazoprevir/elbasvir +/− RBV for 12 or 16 weeks in patients with HCV G1, G4 or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment- experience [Abstract P0886]. In: 50th Annual Meeting of the European Association for the Study of the Liver. 2015: Vienna, Austria.
Zeuzem S, Rockstroh JK, Kwo PY et al. Predictors of response to grazoprevir/elbasvir among HCV genotype 1 (GT1)-infected patients: integrated analysis of phase 2–3 trials [Abstract 700]. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2015: San Francisco, CA.
Buti M, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62(1):32–6.
Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child–Pugh class B cirrhosis (C-salt part A) [Abstract O008]. In: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna, Austria.
•• Afdhal N, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.Manuscript demonstrating efficacy of ledipasvir/sofosbuvir for treatment of chronic hepatitis C infection in treatment naive patients.
•• Kowdley KV, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.Study demonstrating non-inferiority of 8 weeks of ledipasvir/sofosbuvir compared to 12 weeks in specific subgroups of patients with hepatitis C infection.
Terrault, N.A., et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131–40.
de Ledinghen V FH, Dorival C et al., Safety and efficacy of sofosbuvir-containing regimens in the French obervational cohort ANRS C022 HEPATHER. [Abstract P0795]. In: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna, Austria.
Backus LI, et al. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64(2):405–14.
Wilder JM, et al. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology. 2016;63(2):437–44.
O’Brien TR, Lang Kuhs KA, Pfeiffer RM. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis. 2014;1(3):ofu110.
•• Afdhal N, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.Phase 3 trial examining the efficacy of ledipasvir/sofosbuvir for treatment of chronic hepatitis C infection in treatment experienced patients.
Tapper EB, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat, 2017;24(1):22–7.
Bourliere M, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397–404.
Gane EJ, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(3):736–43. e1
Lawitz E, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.
Charlton M, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–59.
Manns M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685–97.
• Ferenci P, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–92.Phase 3 clinical trial examining the efficacy and safety of ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for the treatment of chronic hepatitis C infection in treatment naive patients.
• Zeuzem S, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–14.Phase 3 trial demonstrating efficacy and safety of 12 weeks ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for the treatment of chronic hepatitis C infection in treatment experienced patients.
Andreone P, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–65. e1
Poordad F, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82.
Feld JJ, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016;64(2):301–7.
Everson GT, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163(11):818–26.
Pianko S, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163(11):809–17.
• Feld JJ, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.Phase 3 trial demonstrating efficacy of sofosbuvir/velpatasvir for 12 weeks in treatment naive and experienced hepatitis C patients.
Curry MP, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–28.
Gao M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465(7294):96–100.
Sofia MJ, et al. Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010;53(19):7202–18.
Sulkowski MS, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21.
Wyles DL, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714–25.
Poordad F, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–505.
Welzel TM, Zeuzem S, Petersen J, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program [Abstract 37]. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2015: San Francisco, CA.
Lawitz E, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–65.
Kwo P, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64(2):370–80.
•• Sarrazin C, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(3):501–12. e1Critical manuscript evaluating the prevalence and treatment outcomes with NS5A, NS5B and NS3 RAVs.
Bourlière M, Gordon SC, Ramji A et al. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor-experienced patients with genotype 1–6 infection: the phase 3 POLARIS-1 study [Abstract 194]. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2016: Boston, MA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Dr. Kimberly Forde declares that she has no conflicts of interest. Dr. Debika Bhattacharya has received research support, paid to her institution, from Abbvie, Merck, and Bristol-Myers Squibb.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Hepatitis C
Rights and permissions
About this article
Cite this article
Forde, K.A., Bhattacharya, D. Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. Curr Treat Options Infect Dis 9, 262–276 (2017). https://doi.org/10.1007/s40506-017-0124-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40506-017-0124-x